Effectiveness of anastrozole and cyproterone acetate in two brothers with familial male precocious puberty

J Pediatr Endocrinol Metab. 2008 Oct;21(10):995-1002. doi: 10.1515/jpem.2008.21.10.995.

Abstract

Testotoxicosis is a rare form of precocious puberty caused by a constitutively activating mutation in the luteinizing hormone receptor (LHR) gene. Symptoms include rapid virilization, accelerated growth and reduced adult height. We describe a rare association of testotoxicosis with a metaphyseal chondrodysplasia called cartilage-hair hypoplasia (CHH) and report two brothers with testotoxicosis after 4 years of treatment. The brothers had a T577I mutation in the LHR gene. One brother also presented CHH. The older brother was treated with ketoconazole, then with the aromatase inhibitor anastrozole and the anti-androgen cyproterone acetate. The younger brother received this combination as first-line therapy. Clinical improvements included reductions in growth velocity and bone maturation rate, which should result in taller adult stature. Tolerance was good.

Conclusion: Combined treatment with anastrozole and cyproterone acetate is effective in improving the prognosis of adult height in testotoxicosis.

Publication types

  • Case Reports

MeSH terms

  • Anastrozole
  • Androgen Antagonists / therapeutic use*
  • Aromatase Inhibitors / therapeutic use*
  • Body Height / drug effects
  • Child, Preschool
  • Cyproterone Acetate / therapeutic use*
  • Humans
  • Infant
  • Male
  • Mutation
  • Nitriles / therapeutic use*
  • Puberty, Precocious / drug therapy*
  • Puberty, Precocious / genetics
  • Puberty, Precocious / physiopathology
  • Receptors, LH / genetics
  • Treatment Outcome
  • Triazoles / therapeutic use*

Substances

  • Androgen Antagonists
  • Aromatase Inhibitors
  • Nitriles
  • Receptors, LH
  • Triazoles
  • Anastrozole
  • Cyproterone Acetate